Unum Therapeutics Presents Preclinical Data for BOXR1030 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
05. November 2019 08:30 ET
|
Unum Therapeutics Inc.
- Unum’s first product candidate from its BOXR platform, BOXR1030, is designed to improve T cell functionality in the solid tumor microenvironment - - BOXR1030 T cells co-express the GOT2...
Unum Therapeutics Announces Strategic Focus on Developing Best-in-Class Cellular Therapies for Solid Tumor Cancers
04. November 2019 16:00 ET
|
Unum Therapeutics Inc.
- Solid tumor cancers represent the greatest unmet medical need for targeted cell therapies; Unum’s goals are to more selectively target solid tumors with its ACTR platform candidates and improve T...
Unum Therapeutics Announces Data Presentation at the Upcoming Society for Immunotherapy of Cancer (SITC) Meeting
02. Oktober 2019 07:05 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today...
Unum Therapeutics to Present at Upcoming Industry Conferences in September
05. September 2019 07:00 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today...
Unum Therapeutics to Present at Upcoming September Investor Conferences
26. August 2019 07:05 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today...
Unum Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Updates
12. August 2019 16:05 ET
|
Unum Therapeutics Inc.
- Updated results from Phase 1 trial with ACTR707 in combination with rituximab in adults with relapsed/refractory non-Hodgkin lymphoma confirms the clinical activity achieved in previous cohorts with...
Unum Therapeutics to Review Second Quarter 2019 Financial Results on August 12, 2019
02. August 2019 09:00 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., Aug. 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (Nasdaq: UMRX), a biopharmaceutical company focused on developing potentially curative cellular immunotherapies through its...
Unum Therapeutics Announces New Appointments to its Board of Directors
29. Juli 2019 07:05 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., July 29, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat...
Unum Therapeutics to Present at the Wedbush PacGrow Healthcare Conference
17. Juli 2019 09:00 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., July 17, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat...
Unum Therapeutics Announces Regulatory Update from Phase 1 Trial with ACTR087
02. Juli 2019 16:30 ET
|
Unum Therapeutics Inc.
CAMBRIDGE, Mass., July 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat...